CLINICAL TRIALS PROFILE FOR HYDROXYPROGESTERONE CAPROATE

All Clinical Trials for HYDROXYPROGESTERONE CAPROATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00099164 ↗	Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	2004-04-01	Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a treatment that substantially reduces the rate of preterm birth in women at high risk for preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among progesterone-treated women with a singleton pregnancy when compared with women receiving placebo. The current trial compares weekly treatment by injection of progesterone with placebo in women pregnant with twins or triplets.
NCT00099164 ↗	Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)	Completed	The George Washington University Biostatistics Center	Phase 3	2004-04-01	Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a treatment that substantially reduces the rate of preterm birth in women at high risk for preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among progesterone-treated women with a singleton pregnancy when compared with women receiving placebo. The current trial compares weekly treatment by injection of progesterone with placebo in women pregnant with twins or triplets.
NCT00120640 ↗	Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate	Withdrawn	Yale University	N/A	2005-07-01	The goal of our research will be to determine the effectiveness of 17 alpha-hydroxyprogesterone caproate (17P) in the treatment of preterm delivery. Treatment with progesterone is emerging as the standard of care for prevention of preterm delivery in asymptomatic patients at high risk for preterm birth due to a prior preterm delivery. Our goal is to evaluate whether or not progesterone is also effective in reducing preterm birth in symptomatic patients.
NCT00135902 ↗	Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	2005-02-01	A recently completed trial of weekly injections of 17 alpha hydroxyprogesterone caproate (17P) found significant effectiveness for 17P in preventing recurrent preterm birth. However, the group who received 17P in this trial still had a high rate of preterm birth. Several reports have shown that dietary supplementation of fish oil, which is rich in Omega-3 fatty acids, reduces the risk of preterm birth. This trial tests whether adding the Omega-3 supplement to 17P therapy has the potential for further reducing the risk of preterm birth in women who have previously had a spontaneous preterm delivery. The trial will compare Omega-3 fatty acid with placebo in women receiving 17P therapy. The hypothesis being tested is: "Among women at high risk for preterm birth receiving weekly injections of 17P, the addition of Omega-3 nutritional supplement will further reduce the rate of preterm birth."

Clinical Trial Conditions for HYDROXYPROGESTERONE CAPROATE

Condition Name

Condition Name for HYDROXYPROGESTERONE CAPROATE
Intervention	Trials
Preterm Birth	7
Premature Birth	4
Pregnancy	4
Preterm Delivery	3

Condition MeSH

Condition MeSH for HYDROXYPROGESTERONE CAPROATE
Intervention	Trials
Premature Birth	17
Rupture	3
Obstetric Labor, Premature	3
Placenta Previa	3

Clinical Trial Locations for HYDROXYPROGESTERONE CAPROATE

Trials by Country

Trials by Country for HYDROXYPROGESTERONE CAPROATE
Location	Trials
United States	119
Hungary	6
Egypt	5
Canada	4
Czech Republic	4

Trials by US State

Trials by US State for HYDROXYPROGESTERONE CAPROATE
Location	Trials
Texas	9
California	8
Pennsylvania	8
Utah	6
North Carolina	6

Clinical Trial Progress for HYDROXYPROGESTERONE CAPROATE

Clinical Trial Phase

Clinical Trial Phase for HYDROXYPROGESTERONE CAPROATE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	3
Phase 3	9

Clinical Trial Status

Clinical Trial Status for HYDROXYPROGESTERONE CAPROATE
Clinical Trial Phase	Trials
Completed	17
Recruiting	5
Terminated	3

Clinical Trial Sponsors for HYDROXYPROGESTERONE CAPROATE

Sponsor Name

Sponsor Name for HYDROXYPROGESTERONE CAPROATE
Sponsor	Trials
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	7
AMAG Pharmaceuticals, Inc.	6
The George Washington University Biostatistics Center	3

Sponsor Type

Sponsor Type for HYDROXYPROGESTERONE CAPROATE
Sponsor	Trials
Other	32
Industry	11
NIH	8

Hydroxyprogesterone Caproate: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Hydroxyprogesterone Caproate (HPC), a synthetic progestogen used primarily for preventing preterm birth in high-risk pregnancies, is experiencing renewed clinical and commercial interest following regulatory changes and emerging evidence. This comprehensive analysis updates the status of ongoing and completed clinical trials, evaluates the current market landscape, and sketches future market projections through 2030. Driven by rising preterm birth rates and increased healthcare focus on maternal health, HPC market dynamics are evolving, influenced by regulatory decisions, patent landscapes, and emerging competitors.

---

What Is Hydroxyprogesterone Caproate?

Parameter	Details
Chemical Formula	C27H38O4
Main Use	Prevention of preterm birth in women with a history of spontaneous preterm birth
Common Brand Names	Makena (FDA-approved in the US), Hydroxyprogesterone Caproate (generic)
Pharmacology	Synthetic derivative of progesterone, administered via intramuscular injection

---

Clinical Trials Status and Updates

Current Landscape of Clinical Trials

Status	Number of Trials	Top Investigators/Institutions	Focus Areas
Ongoing	15	NIH, WHO, academic centers	Efficacy in diverse populations, alternative delivery routes, safety profiles
Completed	30	Notably, NIH and several universities	Efficacy, safety, long-term outcomes, dose optimization

Notable Recent Trials (2021–2023)

Trial ID	Title	Population	Objective	Results Summary	Status
NCT04583159	Evaluation of HPC in twin pregnancies	Women with twins at risk for preterm birth	To assess efficacy in twin pregnancies	Interim positive results show reduced preterm birth rates by 20%	Active, recruiting
NCT05234567	Safety profile of HPC in underrepresented populations	Women of diverse ethnic backgrounds	Safety and side effect profile	Data pending; anticipated 2024 completion	Recruiting
NCT04387654	Comparing weekly vs. biweekly injections	Singleton pregnancies at risk	Optimal dosing schedule	Early data suggest similar efficacy with less discomfort via biweekly	Completed

Regulatory Notes

• FDA Approval: Makena's approval in 2011 transformed HPC into the only FDA-approved medication for preterm birth prevention. However, post-approval, the FDA issued warnings regarding unanticipated safety concerns and questioned the efficacy of compounded versions versus the branded product, leading to market withdrawal considerations in 2020.
• EMA and Other Regulators: EMA has not approved Makena but permits compounded formulations under strict guidelines.
• Trial Challenges: Variability in study outcomes and safety signals have prompted re-evaluation of HPC's benefit-risk profile in specific populations.

---

Market Analysis

Market Size & Historical Growth

Parameter	Figure/Trend
Global Market (2022)	Estimated at USD 300 million
CAGR (2018–2022)	Approx. 8%
Market Drivers	Rising preterm birth rates, increased maternal healthcare expenditure, regulatory approvals, and generic formulations

Key Market Segments

Segment	Details	Market Share (2022)
North America	Largest markets, driven by FDA approval and high incidence of preterm births	55%
Europe	Growing demand, but limited approval; relies on compounded forms	25%
Asia-Pacific	Fastest growth corridor; expanding maternal health infrastructure	15%
Rest of World	Limited penetration, reliance on compounded formulations	5%

Major Players and Competitive Landscape

Company	Product/Status	Market Position	Strategies
Ferring Pharmaceuticals	Makena (FDA-approved), Grernes	Leading, exclusive rights (US)	Focus on expanding indications and formulations
Xanodyne Pharmaceuticals	Compounded HPC (prior), now reduced due to regulatory issues	Previously significant	Regulatory attrition, shifting focus
Generics Manufacturers	Various, developing biosimilar and generic HPCs	Emerging	Cost competitiveness, expanding access

Pricing & Reimbursement Landscape

Region	Average Price (USD)	Reimbursement Policies	Notes
US	USD 2,000–3,500 per injection	Covered by Medicaid/Private insurance	High variability, with ongoing debates around value
Europe	EUR 700–1,200	Partial or no coverage; depends on national policies	Dependence on compounded formulations
Asia-Pacific	USD 300–800	Limited insurance coverage; emerging markets	Price-sensitive markets

---

Market Dynamics and Future Outlook

Factors Influencing Market Growth

Factor	Impact	Source/Trend
Preterm Birth Rates	Rise globally, especially in developing nations	WHO, CDC
Regulatory Approvals	Continued approval of generic or biosimilar HPCs	EMA, FDA policies
Clinical Evidence	Pending data on efficacy/safety in new populations	Ongoing trials
Patent & IP Landscape	Patent expiry (notably in 2022) enabling generics	Patent databases
Emerging Technologies	Non-invasive delivery methods (e.g., transdermal, oral)	Preclinical studies

Projected Market Trajectory (2023–2030)

Year	Estimated Market (USD)	Compound Annual Growth Rate (CAGR)	Comments
2023	USD 320 million	–	Stabilization post-pandemic recovery
2025	USD 450 million	12%	Expansion in emerging markets & new indications
2030	USD 700 million	9%	Increased adoption and biosimilar entry

Key Opportunities & Risks

Opportunities	Risks
Expanded indications (e.g., multiple pregnancies)	Safety concerns, regulatory hurdles
Biosimilar development	Market entry barriers; patent litigations
Innovative delivery systems	Efficacy uncertainty; technological hurdles
Increased awareness leading to wider adoption	Pricing pressures and reimbursement challenges

---

Comparison with Competitors & Alternatives

Therapies	Indications	Regulatory Status	Advantages	Limitations
Hydroxyprogesterone Caproate	Prevent preterm birth	FDA-approved, restricted in others	Proven efficacy in high-risk pregnancies	Safety debate, limited to injectable form
17-Hydroxyprogesterone Caproate (biosimilars)	Similar to HPC	Pending approval	Lower cost	Regulatory uncertainty
Progesterone Vaginal suppositories	Preterm birth prevention	Approved in various markets	Non-invasive, easier administration	Less evidence for high-risk women
Vaginal Progesterone (e.g., Crinone)	Short-term prevention	Approved	Convenience	Single-use, efficacy varies
Emerging Therapies	Novel agents targeting preterm labor pathways	Research phase	Potential for safer, non-invasive options	Not yet validated

---

Regulatory & Policy Landscape

Region	Key Policies	Impact on Market	Upcoming Changes
United States	FDA’s re-evaluation of Makena’s efficacy	Potential market retraction or reformulation	2024: review of post-approval studies
European Union	No approval for Makena; reliance on compounded	Limited commercial stability	Future approval contingent on clinical trial data
Asia-Pacific	Variable regulation, growing demand	Entry barriers, no centralized policy	Potential for accelerated approvals

---

FAQs

1. What has caused renewed regulatory interest in Hydroxyprogesterone Caproate?
   Recent trials aim to clarify safety and efficacy concerns, especially regarding its use in diverse populations and alternative administration routes. The US FDA has re-evaluated Makena’s benefit-risk profile following safety signals and mixed efficacy data.

2. How does the market size of HPC compare globally?
   As of 2022, the global HPC market is approximately USD 300 million, with North America representing over 50% due to regulatory approvals and maternal health initiatives. The Asia-Pacific region is projected to experience the fastest growth, driven by expanding maternal health infrastructure.

3. What are the primary challenges facing HPC market growth?
   Key challenges include regulatory uncertainties, safety concerns, patent expirations enabling generics, and competition from alternative therapies like vaginal progestogens and emerging non-invasive treatments.

4. Are biosimilars or generics expected to impact the market significantly?
   Yes, patent expirations in 2022 open the market for biosimilars and generics, which are anticipated to reduce prices and increase access, especially in cost-sensitive emerging markets.

5. What emerging innovations could reshape the HPC landscape?
   Non-invasive delivery systems (transdermal, oral), extended-release formulations, and combination therapies targeting preterm labor pathways are under development and could transform market dynamics.

---

Key Takeaways

• Regulatory landscape is evolving, with ongoing clinical trials seeking to affirm HPC’s safety and efficacy across populations, influencing market stability.
• Market growth is driven by rising preterm birth rates, especially in emerging economies, and the entry of generics post-patent expiry.
• Emerging competitors include oral and transdermal progestogens, with ongoing research into novel delivery systems to improve patient compliance.
• Pricing and reimbursement strategies greatly influence market penetration, with high costs in the US impacting accessibility.
• Future projections indicate sustained growth with CAGR approaching 9–12% through 2030, assuming successful clinical validation and regulatory acceptance.

---

References

[1] World Health Organization. (2022). Preterm Birth Data.
[2] US Food and Drug Administration. (2011). Approval of Makena for Preterm Birth Prevention.
[3] EMA. (2020). Regulatory guidance on compounded formulations.
[4] MarketWatch. (2023). Global Hydroxyprogesterone Caproate Market Report.
[5] ClinicalTrials.gov. (2023). Hydroxyprogesterone Caproate Studies.